MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkin"

  • 2016 International Congress

    Two cases of parkinsonism with atypical genetics

    J.A. Ribeiro, F. Moreira, J. Beato-Coelho, A.S. Morgadinho, M.R. Almeida, C. Januário (Coimbra, Portugal)

    Objective: To report and discuss two unrelated patients carrying heterozygous mutations in both Parkin (PARK2) and Glucocerebrosidase (GBA) gene, with atypical Parkinsonian features. Background: Parkin…
  • 2016 International Congress

    Sonographic investigation of Pisa syndrome in Parkinson’s disease

    J. Shiraishi, T. Okazaki, M. Mizuba, K. Kajiwara, S. Saeki, R. Matsugaki, T. Takei, T. Uozumi (Fukuoka, Japan)

    Objective: We hypothesized that the trunk muscles might have an impact on Pisa syndrome, so we performed a sonographic investigation of the trunk muscles of…
  • 2016 International Congress

    PINK1-dependent clearance of depolarized mitochondria is driven by the UPS and can occur independently of (macro)autophagy

    A. Rakovic, J. Ziegler, C.U. Mårtensson, J. Prasuhn, K. Shurkewitsch, P. König, H.L. Paulson, C. Klein (Luebeck, Germany)

    Objective: To disect the role of macroautophagy in PINK1-/Parkin-dependent removal of depolarized mitochondria. Background: The ubiquitin ligase Parkin and mitochondrial kinase PINK1 function together in…
  • 2016 International Congress

    Counteracting PINK1/parkin deficiency by activating alternative mitophagic pathway: a potential therapeutic intervention for Parkinson’s disease

    B. Koentjoro, J.S. Park, C.M. Sue (Sydney, Australia)

    Objective: To identify a new therapeutic target for developing neuroprotective treatment in Parkinson's disease (PD) by improving mitochondrial function through restoration of mitochondrial quality control…
  • 2016 International Congress

    Analysis of relationships between spinal deformity and walking ability in Parkinson’s disease patients

    Y. Nakamura, Y. Machida, T. Hanawa, M. Kanai, K. Tajima, S. Asano (Satte, Japan)

    Objective: To determine the impact on walking ability of spinal deformity and imbalance as distinct from movement disorder in Parkinson's disease (PD). Background: Despite a…
  • 2016 International Congress

    Neuromelanin imaging is useful for monitoring disease progression in Parkinson’s disease and PARK2

    T. Hatano, A. Okuzumi, K. Kamagata, K. Daida, D. Taniguchi, M. Hori, H. Yoshino, S. Aoki, N. Hattori (Tokyo, Japan)

    Objective: Using neuromelanin (NM)-MRI, we analyzed whether disease severity and MF is associated with the degree of dopaminergic neuronal degeneration in the substantial nigra compacta…
  • 2016 International Congress

    Heterozygous PINK1 p.G411S mutation increases risk for Parkinson’s disease (PD)

    W. Springer, A. Puschmann, F.C. Fiesel, M. Ando, T.R. Caulfield, K. Ogaki, M.G. Heckman, R. Hudec, E.D. James, G. Opala, J. Siuda, M. Boczarska-Jedynak, A. Friedman, D. Koziorowski, J.O. Aasly, T. Lynch, G.D. Mellick, M. Mohan, P.A. Silburn, Y. Sanotsky, C. Vilariño-Güell, M.J. Farrer, T. Dawson, Z.K. Wszolek, O.A. Ross (Jacksonville, FL, USA)

    Objective: To investigate the possible disease-association and pathogenic mechanisms of heterozygous PINK1 mutations from a genetic, functional, and structural perspective. Background: It has been postulated…
  • 2016 International Congress

    Mitochondrial Hsp90 inhibitor G-TTP triggers PINK1/parkin-dependent mitochondrial quality control

    F.C. Fiesel, J.D. Elle, H.R. Anneliese, H. Roman, S. Wolfdieter (Jacksonville, FL, USA)

    Objective: To characterize the response of cells treated with Gamitrinib-triphenylphosphonium (G-TTP) a mitochondrial targeted inhibitor of the chaperone Hsp90. Background: Upon dissipation of the mitochondrial…
  • 2016 International Congress

    Work-related stress and risk for Parkinson’s disease

    J. Sieurin, R. Andel, E.G. Valdes, N.L. Pedersen, K. Wirdefeldt (Stockholm, Sweden)

    Objective: To explore the association between work-related stress (job control and job demands) and the risk for Parkinson's disease (PD). Background: Chronic stress is associated…
  • 2016 International Congress

    Temporal working memory deficit in Parkinson’s disease

    B. Degos, I. Ameqrane, S. Rivaud-Péchoux, P. Pouget, M. Missal (Paris, France)

    Objective: To investigate whether temporal working memory (TWM) could be impacted in Parkinson's disease (PD). We also tested whether idiopathic PD patients (iPD) could be…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • #23285 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley